READ-ONLY DIGITIZATION RESULT
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis.
Liver Cancer · 2026-Jun · PMID 42338692
Panel DOR_in_Japanese_patients质量警告待 EXE 对齐验证
Duration of response
Fig. 3. Kaplan-Meier estimate of DOR in all randomized Japanese patients with a confirmed objective response. Kaplan-Meier estimate based on all patients with a confirmed complete or partial response per BICR using Response Evaluation Criteria in Solid Tumors, version 1.1 ( n = 14 in the nivolumab plus ipilimumab group; n = 5 in the lenvatinib or sorafenib group). Tick marks indicate censored data. BICR, blinded independent central review; CI, confidence interval; DOR, duration of response; HR, hazard ratio; IPI, ipilimumab; LEN, lenvatinib; mo, months; NE, not evaluable; NIVO, nivolumab; NR, not reached; SOR, sorafenib.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-24T15:13:01+00:00 |